Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate Starting Doses in Rheumatoid Arthritis
NCT01404429Phase 4Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- May 2011
- Primary completion
- Jun 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoints: Mean Change in the DAS28-3 (Disease Activity Score Using 28 Joints and Using 3 Variables) at 12 weeks and Patients With Good Response at 3 months. Started May 2011; status: completed.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01404429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01404429.